Search Menu
Photonics Media Photonics Buyers' Guide Photonics EDU Photonics Spectra BioPhotonics EuroPhotonics Industrial Photonics Photonics Showcase Photonics ProdSpec Photonics Handbook
More News
2016 Photonics Buyers' Guide Clearance! – Use Coupon Code FC16 to save 60%!
Email Facebook Twitter Google+ LinkedIn Comments

Viralytics strengthens portfolio

Photonics Spectra
Jun 2009
In Sydney, Australia, Viralytics Ltd. has received a US patent for the use of Echoviruses, including the proprietary Evatak formulation of Echovirus Type 1, to treat all cancers expressing the integrin a2b1 molecule. Included are ovarian, prostate and gastric forms, all of which express high levels of the molecule on their surfaces. The patent provides the company with the exclusive use of the viruses in this manner until 2023, and it strengthens Viralytics’ intellectual property portfolio.

Terms & Conditions Privacy Policy About Us Contact Us
back to top

Facebook Twitter Instagram LinkedIn YouTube RSS
©2016 Photonics Media
x Subscribe to Photonics Spectra magazine - FREE!